Literature DB >> 20865648

Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men.

J W Hong1, J Y Kim, Y-E Kim, E J Lee.   

Abstract

Patients with hypopituitarism have the feature of metabolic syndrome, including central obesity, insulin resistance, and dyslipidemia. Because metabolic syndrome, including insulin resistance, is the main pathogenesis of the development of nonalcoholic fatty liver disease (NAFLD), we considered that patients diagnosed with hypopituitarism have an increased risk of developing NAFLD. We compared control subjects and hypopituitary men in metabolic parameters and the frequency of fatty liver on abdominal ultrasonography, and analyzed associating factors with the severity of the fatty liver in patients with hypopituitarism. 34 male patients with hypopituitarism and 40 age and sex-matched control subjects were included. The frequency of fatty liver on abdominal ultrasonography was significantly higher in hypopituitary men compared to control subjects (32.5% vs. 70.6%, p=0.001). Ln CRP and free fatty acids were significantly elevated in hypopituitary patients with fatty liver compared to patients without fatty liver. Ln GH was significantly lower in hypopituitary patients with fatty liver. The severity of fatty liver on abdominal ultrasonography correlated with negatively Ln GH, after adjusting for the BMI effect (p=0.020). There is a difference only between the severe fatty liver group and normal liver group in the analysis of the mean Ln GH level between 4 groups according to the severity of fatty liver (p=0.036). In conclusion, NAFLD is more common in hypopituitary patients than control subject. Severe growth hormone deficiency in hypopituitarism was associated with the severe degree of hepatic steatosis in NAFLD. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20865648     DOI: 10.1055/s-0030-1265217

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  17 in total

1.  Factors associated with significant liver fibrosis assessed using transient elastography in general population.

Authors:  Seng Chan You; Kwang Joon Kim; Seung Up Kim; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Won Jae Lee; Kwang-Hyub Han
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

2.  The effect of recombinant human growth hormone with or without rosiglitazone on hepatic fat content in HIV-1-infected individuals: a randomized clinical trial.

Authors:  Donald P Kotler; Qing He; Ellen S Engelson; Jeanine B Albu; Marshall J Glesby
Journal:  Antivir Ther       Date:  2014-12-23

3.  Prevalence of pituitary hormone dysfunction, metabolic syndrome, and impaired quality of life in retired professional football players: a prospective study.

Authors:  Daniel F Kelly; Charlene Chaloner; Diana Evans; Amy Mathews; Pejman Cohan; Christina Wang; Ronald Swerdloff; Myung-Shin Sim; Jihey Lee; Mathew J Wright; Claudia Kernan; Garni Barkhoudarian; Kevin C J Yuen; Kevin Guskiewicz
Journal:  J Neurotrauma       Date:  2014-05-08       Impact factor: 5.269

Review 4.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

5.  CircScd1 Promotes Fatty Liver Disease via the Janus Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway.

Authors:  Peifei Li; Keshu Shan; Yi Liu; Yu Zhang; Lu Xu; Lei Xu
Journal:  Dig Dis Sci       Date:  2018-09-27       Impact factor: 3.199

Review 6.  Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice.

Authors:  Sherwyn Schwartz; Jean Lucas; Mark H DeLegge
Journal:  touchREV Endocrinol       Date:  2021-09-14

7.  Growth hormone cocktail improves hepatopulmonary syndrome secondary to hypopituitarism: A case report.

Authors:  Wen Ji; Min Nie; Jiang-Feng Mao; Hong-Bing Zhang; Xi Wang; Xue-Yan Wu
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

8.  Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study.

Authors:  Lei Xu; Chengfu Xu; Chaohui Yu; Min Miao; Xuequn Zhang; Zhongwei Zhu; Xiaoyun Ding; Youming Li
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

Review 9.  The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver.

Authors:  Yutaka Takahashi
Journal:  Int J Mol Sci       Date:  2017-07-05       Impact factor: 5.923

10.  Nonalcoholic fatty liver disease in long-term survivors of childhood-onset craniopharyngioma.

Authors:  So Yoon Jung; Yun Jeong Lee; Hye Jin Lee; Young Ah Lee; Jin Soo Moon; Jae Sung Ko; Sei Won Yang; Choong Ho Shin
Journal:  Ann Pediatr Endocrinol Metab       Date:  2017-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.